Counts of myeloid neoplasms before and after standardization of mastocytosis evaluations
| . | 1 July 2023 (n) . | 1 July 2021 (n) . |
|---|---|---|
| CM | ||
| Adult-onset monomorphic MPCM | 15 | 33 |
| Pediatric-onset monomorphic MPCM | 0 | 1 |
| Pediatric-onset DCM | 2 | 5 |
| SM | ||
| Presumed indolent SM∗ | 7 | 0 |
| Indolent SM† | 79 | 44 |
| Aggressive SM | 3 | 1 |
| SM with an associated myeloid hematologic neoplasm | 3 | 2 |
| Mast cell leukemia† | 1 | 1 |
| Non-SM clonal mast cell disorder | ||
| Monoclonal mast cell activation syndrome | 1 | 0 |
| Other myeloid neoplasms | ||
| Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRα fusion | 2 | 1 |
| Myelodysplastic syndrome | 1 | 1 |
| Chronic myelomonocytic leukemia | 1 | 0 |
| Total | 115 | 89 |
| . | 1 July 2023 (n) . | 1 July 2021 (n) . |
|---|---|---|
| CM | ||
| Adult-onset monomorphic MPCM | 15 | 33 |
| Pediatric-onset monomorphic MPCM | 0 | 1 |
| Pediatric-onset DCM | 2 | 5 |
| SM | ||
| Presumed indolent SM∗ | 7 | 0 |
| Indolent SM† | 79 | 44 |
| Aggressive SM | 3 | 1 |
| SM with an associated myeloid hematologic neoplasm | 3 | 2 |
| Mast cell leukemia† | 1 | 1 |
| Non-SM clonal mast cell disorder | ||
| Monoclonal mast cell activation syndrome | 1 | 0 |
| Other myeloid neoplasms | ||
| Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRα fusion | 2 | 1 |
| Myelodysplastic syndrome | 1 | 1 |
| Chronic myelomonocytic leukemia | 1 | 0 |
| Total | 115 | 89 |
All patients counted on 1 July 2021, continued to be active beneficiaries, and were counted on 1 July 2023. Any counts that decreased from 2021 to 2023 reflect reclassification of the myeloid neoplasm.
Presumed ISM reflects patients who had detectable KIT p.D816V in PB but did not have a BMB by 1 July 2023.
There were 4 patients with a well-differentiated morphologic phenotype by 1 July 2023 including 3 with ISM and 1 with mast cell leukemia.